Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC

Cache Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,548 shares of the biopharmaceutical company’s stock after selling 2,752 shares during the period. Regeneron Pharmaceuticals accounts for about 0.3% of Cache Advisors LLC’s holdings, making the stock its 22nd biggest position. Cache Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. Finally, FNY Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,774 shares of company stock valued at $2,942,738. 7.02% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on REGN shares. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a report on Wednesday. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Finally, Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $810.78.

Regeneron Pharmaceuticals Trading Up 2.0%

REGN stock opened at $775.53 on Thursday. The company has a market cap of $81.99 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 2.02 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $766.90 and a 200-day simple moving average of $717.58. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $12.07 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.